Skin aging
Conditions
Interventions
Test group:Restylane Vital Combined with Skinceuticals HA Intensifier Multi-functional Serum
Control group:Restylane Vital
Sponsors
Dermatology Hospital, Southern Medical University
Eligibility
Sex/Gender
All
Age
30 Years to 55 Years
Inclusion criteria
Inclusion criteria: 1. Aged 30-55 years old (inclusive), male or female; 2. Subjects with early to moderate facial aging showed rough, loose skin, lack of elasticity and luster; 3. There were multiple wrinkles and fine lines on the face (periocular/nasolabial fold/perioral, etc.), a trend of static fine lines in the decree or puppet lines area, and signs of sagging on the lower face; 4. Subjects with consistent facial skin status on both sides and plan to receive cross-linked sodium hyaluronate injection; 5. Subjects are willing to actively cooperate with the study visit and maintain the regularity of life during the study; 6. Subjects agree not to use any cosmetics, drugs and health products that have an impact on the results during the study; 7. Subjects can read and understand all the contents of the informed consent form, and voluntarily sign the informed consent form (ICF).
Exclusion criteria
Exclusion criteria: 1. Subjects with skin diseases, infections, inflammation on the face that may affect the study treatment and outcome judgment; 2. Subjects with known intolerance or hypersensitivity to hyaluronic acid, crosslinking agents, and or lidocaine; 3. Subjects with scar constitution or prone to pigmentation; 4. Subjects with active autoimmune diseases, malignant tumors, immune defects, severe cardiovascular and cerebrovascular diseases, severe psychological disorders or mental illness; 5. Subjects who have received medical treatment (photoelectric, tightening, filling, etc.) or plan to receive other medical treatment items and drugs during this treatment within the past 30 days; 6. Subjects who have participated in or are participating in drug clinical trials or other studies within the past 30 days; 7. Subjects who have oral and topical cosmetic products that may affect the study results in the past 2 weeks; 8. Subjects who have used drugs systematically in the past 1 week that may affect the study results; 9. Female subjects who are pregnant, lactating or planning to become pregnant; 10. Other subjects who are not suitable for participating in this study as assessed by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change from baseline in face questionnaire (Face-Q) scale score; | — |
Secondary
| Measure | Time frame |
|---|---|
| Change from baseline in FACE-Q Scale Score;Change from baseline in skin Fine line Scale scores;Change from baseline in skin elasticity;Change from baseline in dermal density;Change from baseline in transepidermal water loss;Change from baseline in skin water content;Change from baseline in skin fine lines;Change from baseline in skin pH; | — |
Countries
China
Contacts
Public ContactBin Yang
Dermatology Hospital, Southern Medical University
Outcome results
None listed